IT WAS previously reported that neomycin in daily oral doses of 1.5 to 2 Gm. reduced serum cholesterol levels in man. 2 An extension of these observations, the effect of other antibacterial drugs, and studies on the mechanisms of action are reported here.
ANTIBACTERIAL DRUGS AND SERUM CHOLESTEROL5 showed a fall in serum cholesterol, the mean decrease being 21 per cent. Serum cholesterol level reached a low point after 1 to 3 weeks of neomycin administration and remained there as long as neomycin was administered, returning to control levels 1 to 8 weeks later (figs. 1, 2, and 3). More complete studies of the serum lipids were made in 10 patients, eight of whom had clinical vascular disease or diabetes mellitus. The concentration of esterified cholesterol and of phospholipids decreased in the serum in proportion to the fall of total cholesterol. The average of the esterified fraction of cholesterol of the 10 patients was 78 per cent of the total during the control period and 77 per cent during the administration of neomycin. The average cholesterol-phospholipid ratio was 1.2, both before and during neomycin administration. The average concentration of beta-lipoprotein cholesterol in the serum was 83 per cent of the total cholesterol during the control period and 82 per cent after the reduction of serum cholesterol by neomycin.
Oral administration of neomycin was combined with other antibacterial drugs in seven instances. The second drug was added after the concentration of serum cholesterol was reduced by neomvein to its low point. Two
Circulation, Volume XXIV, September 1961 grams of mandelamine for 2 weeks, 15 Gm. of phthalylsulfathiazole for 5 weeks, 300 mg. of isoniazid for 7 weeks, and 1 Gm. of oxytetracycline for 3 weeks were added daily to the neomyein regimen without influencing the effect of neomycin ( fig. 3) .
The results of daily intramuscular administration of 60 mg. of neomycin are summarized in table 3. In the 10 patients studied, the daily intramuscular injection of the drug failed to alter the concentration of serum cholesterol (figs. 1 and 3).
No major side effects occurred during the administration of neomycin. Ten of the 30 patients who were given neomycin orally developed temporary, mild diarrhea that was usually controlled easily with tincture of paregoric; in one case neomycin had to be discontinued at the end of 6 weeks. The weight of the patients did not vary more than 2 lbs. in a period of 6 months. The hematopoietic, hepatic, and renal functions were not altered.
Neamine, given by mouth, also reduced serum cholesterol in three patients (table 4 and fig. 2 ).
The results of PAS administration at different dose levels are shown in table 5. Eleven of the 15 subjects had pulmonary tuberculosis.
These patients were given 300 mg. of isoniazid 
Results
In the three patients who received 1 Four hospitalized patients (table 8) were studied who underwent cholecystectomy because of cholelithiasis and cholecystitis. A T-tube was placed in the common hepatic duct by the surgeon, through which drained 250 to 600 ml. of bile daily prior to and during the experiment. The tests were performed 4 to 17 days after the operation. The patients were afebrile, out of bed, had normal kidney function, were orally fed, and were not given other antibacterial drugs for 6 days or longer at the time of the experiment. A single oral dose of 2 Gm. of neomycin was given to four patients. Subsequently, (in 2-to 4-day intervals) a single intramuscular injection of 60 mg. was administered to three of these subjects. Serum, bile, and urine specimens were collected before and serially during the 24 hours that followed administration of the drug.
Serum and urinary concentrations of neomycin were determined as described. administration of the drug alters significantly the character of the intestinal bacterial flora.6 It is generally accepted that neomycin is poorly absorbed from the gastrointestinal tract,8 whereas rapid diffusion and distribution of the drug are observed after its parenteral administration. In the present study the intramuscular administration of 60 mg. of neomycin resulted in 12-fold higher average serum concentrations than oral doses of 2 Gm. Since oral neomycin lowered serum cholesterol concentrations significantly, whereas the above intramuscular doses failed to alter the level of serum cholesterol, it is suggested that the effect of the drug is dependent upon its activity in the gastrointestinal tract. Furthermore, the experiments on the biliary excretion of neomycin suggest that the biliary excretion of the drug is probably derived from the general circulation, and that the existence of an enterohepatic circulation of the drug, and thus its direct action upon the liver cell when administered orally, is unlikely.
In contrast to data on man neomycin appears to be ineffective in lowering the serum cholesterol level in normal and cholesterolfed rats,9 and in cholesterol-fed rabbits.'0 In fact, in rats fed cholesterol and cholic acid, neomycin appeared to increase serum cholesterol concentrations and aortic sudanophia."l In the present study, the oral use of neomycin seemed to be well tolerated over long periods of time in patients without kidney impairment. The only side effect was a temporary mild diarrhea in about one third of the subjects treated orally. Any relation of the cholesterol-lowering activity of the drug to diarrhea is highly unlikely, since the duration of diarrhea was insignificant compared to the length of the experiments, and patients without diarrhea exhibited similar reduction in serum cholesterol. Furthermore, the administration of other antibiotics, which failed to lower serum cholesterol levels, caused diarrhea as frequently as neomycin. Finally no patient lost more than 2 lbs. of weight in the group treated with neomycin. Stormont et al. ' 2 reported severe diarrhea in three of 68 cirrhotic patients treated for hepatic coma with oral doses of 4 to 8 Gm. of neomycin daily. Monilia was cultured in the stools of two of these three cases. Last and Sherlock'3 reported the case of a patient with cirrhosis and hepatic coma, treated by oral daily doses of initially 12 then 4 Gm. of neomycin for over 140 days, followed by deafness, which was ascribed to the toxicity of the drug.
Faloon, Jacobson, and associates,'4' 15 described an "experimental malabsorption syndrome " associated with steatorrhea and morphologic changes of jejunal mucosal6 following daily oral doses of 12 Gm. of neomycin. This syndrome had to be considered in searching for the mechanism of the cholesterol-lowering action of the drug, although in the present study serum cholesterol concentrations were reduced with considerably lower doses of neomycin. Radioactive fat-absorption tests, in the present study, have indicated that the long-term oral administration of 2 Gm. of neomyein per day, accompanied by significant reduction of serum cholesterol concentrations, resulted in no alteration in the normal fat-absorption patterns in two subjects, and in a delayed but complete absorp- Results of radioactive fat-absorption tests in four patients after long-term administration of neomycin and during control periods.
tion of fats in two other patients. These data suggest that the cholesterol-reducing activity of neomycin is not dependent for its effect on absorption of dietary fats. Among the diverse antibacterial drugs used in this study, the antibacterial activity and molecular structure of neamine and kanamycin resemble that of neomycin.6 17 The mechanism of their moderate cholesterol-lowering effect is possibly similar to that of neomycin. The oral use of PAS may cause irritation of the gastrointestinal mucosa and was reported to result in hepatic toxicity. 18 ported that the addition of chlortetracycline to the regimen of cholesterol-fed rabbits augmented the serum cholesterol concentrations and vascular atheromatosis of the animals.
There is no evidence available to explain the serum cholesterol-lowering effect of these diverse antibacterial drugs. Although PAS and chlortetracycline are readily absorbed, one cannot rule out the possibility that their action would be mediated through changes in the gastrointestinal tract. There is no close chemical resemblance between the molecular structures of PAS or chlortetracycline and that of neomycin. The only common denominator between these substances is their antibacterial activity. It should be pointed out that, although a variety of other antibacterial drugs failed to lower serum cholesterol con- esterified fraction of cholesterol and the concentration of phospholipids decreased in the serum in proportion to total cholesterol and the distribution of cholesterol between the alpha-and beta-lipoproteins remained unchanged during neomycin administration.
Combination of oral neomycin with mandelamine, phthalylsulfathiazole, isoniazid, oxytetracycline, and tetracycline did not influence the lowering effect of neomycin on serum cholesterol levels.
Serum levels of neomycin after intramuscular injections of 60 mg. in 10 subjects averaged 12 times higher concentrations than was produced by the oral administration of 2 Gm. of neomycin. The intramuscular administration of 60 mg. of neomycin daily to 10 patients for 3 weeks failed to alter serum cholesterol concentrations. This suggests that the cholesterol-lowering effect of neomycin depends upon its action in the gastrointestinal tract.
The concentration of neomycin was serially determined in the bile, serum, and urine of four patients. Biliary concentrations were higher, or of the same order of magnitude, after intramuscular than after oral administration of the drug. Therefore enterohepatic circulation of neomycin is unlikely.
Radioactive fat-absorption tests following the reduction of serum cholesterol by longterm oral administration of neomycin showed that the absorption of dietary fats was normal in two patients and delayed but complete in two other subjects, suggesting that the cholesterol-reducing activity of neomycin is not dependent on its effect on absorption of dietary fats.
The daily oral administration for The oral administration of phthalylsulfathiazole, isoniazid, penicillin, dihydrostreptomycin, oxytetracycline, chloramphenicol, polymyxin, erythromycin, novobiocin, bacitracin, and viomycin failed to alter serum cholesterol concentrations.
The possible role of the intestinal bacterial flora in the cholesterol-lowering effect of neomycin and other antibacterial drugs, and the general relationship of intestinal bacteria to cholesterol metabolism, were discussed.
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